OABI Profile
OmniAb, Inc., headquartered in Emeryville, California, is a leading biotechnology company specializing in advanced therapeutic antibody discovery technologies. Established in 2012, OmniAb provides innovative solutions that enable the development of next-generation therapeutics through its cutting-edge discovery platform. The company’s technology leverages proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically engineered to produce human-like antibodies, facilitating the creation of human therapeutic candidates.
The OmniAb platform stands out for its ability to deliver a broad range of antibody repertoires and screening technologies. This platform is integral for industry partners seeking to advance their therapeutic programs by accessing diverse and high-quality antibody libraries. OmniRat, OmniChicken, and OmniMouse are central to this platform, each offering unique advantages in antibody development. OmniRat is designed to produce antibodies with human sequences, enhancing the development of human therapeutic candidates. OmniChicken provides valuable insights for bispecific antibody applications, utilizing a common light chain approach to address complex therapeutic needs. OmniMouse extends the platform's capabilities by contributing to the discovery of human antibodies with high affinity and specificity.
Additionally, OmniAb’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) technologies cater to the growing demand for bispecific antibodies, a key area in modern therapeutic development. These technologies are designed to address various therapeutic challenges through innovative approaches, such as the common light chain strategy. Meanwhile, OmniTaur introduces a unique offering with cow antibodies that possess distinctive structural attributes, making it particularly effective for targeting complex antigens and addressing difficult-to-treat diseases.
OmniAb’s commitment to advancing antibody discovery and development positions it as a critical player in the biotechnology sector. By providing state-of-the-art technologies and a comprehensive platform for antibody generation, OmniAb supports the pharmaceutical and biotechnology industries in developing groundbreaking therapies. Through ongoing innovation and collaboration, OmniAb continues to drive progress in therapeutic discovery, helping to bring new and effective treatments to market.
|
